Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Consistency of MGMT Promoter Methylation Levels in Recurrent Gliomas and Its Impact on Temozolomide Rechallenge

  • By

  • Henry Noren

  • Gabriella Pelofsky

  • Brianna Suffren

  • Laura Mittelman

  • Christine Yohn

  • Aminah Twyman

  • Christopher A. Febres-Aldana

  • Arevik Abramyan

  • Aparna Sertil

  • Randy S. D’Amico

  • Jonathan H. Sherman

  • Morana Vojnic

  • September 16, 2026

Share

Original Source(s)

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

  • by Henry Noren, Gabriella Pelofsky, Brianna Suffren, Laura Mittelman, Christine Yohn, Aminah Twyman, Christopher A. Febres-Aldana, Arevik Abramyan, Aparna Sertil, Randy S. D’Amico, Jonathan H. Sherman, Morana Vojnic

  • September 16, 2026

Related Content

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling